Untersuchung einer Umstellung auf MK-1439A von einem Behandlungsregime auf Basis von mit Ritonavir verstärkten Proteasehemmern bei HIV-1-infizierten Patienten.

Drug: Doravirine, Tenofovir, Lamivudine;Drug: Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor;Drug: Baseline regimen of cobicistat-boosted elvitegravir;Drug: Baseline regimen of a non-nucleoside reverse transcriptase inhibitor;Drug: Baseline regimen of two nucleoside reverse transcriptase inhibitors

Gender: All
Maximum age: N/A
Minimum age: 18 Years

Inclusion Criteria:

- At least 18 years of age on the day of signing the informed consent.

- Understand the study procedures and voluntarily agree to participate by giving written
informed consent for the trial.

- Have plasma HIV-1 RNA levels below the limit of quantification (BLoQ) (<40 copies/mL
by the Abbott RealTime HIV-1 Assay as determined by the central laboratory) at the
screening visit.

- Receiving antiretroviral therapy with a ritonavir- or cobicistat-boosted protease
inhibitor (atazanavir, darunavir, or lopinavir) or cobicistat-boosted elvitegravir or
a NNRTI (specifically, efavirenz, nevirapine, or rilpivirine) in combination with 2
NRTIs (and no other antiretroviral therapy) continuously for >= 6 months.

- Receiving first or second retroviral regimen (participants receiving a NNRTI at
Screening must be on their first retroviral regimen)

- No history of using an experimental NNRTI

- Has a genotype prior to starting his/her initial antiretroviral regimen and no known
resistance to any of the study agents

- Not receiving lipid lowering therapy or on a stable dose of lipid lowering therapy at
the time of enrollment

- Has the following laboratory values at screening within 30 days prior to the treatment
phase of this study: Alkaline phosphatase = 3.0 x upper limit of normal (ULN), Serum
aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT) = 5.0 x ULN,
and Hemoglobin =9.0 g/dL (if female) or =10.0 g/dL (if male)

- Has a calculated creatinine clearance at the time of screening = 50 mL/min, based on
the Cockcroft-Gault equation

- Male or female participant not of reproductive potential or, if of reproductive
potential, agrees to avoid becoming pregnant or impregnating a partner while receiving
study drug and for 14 days after the last dose of study drug by complying with one of
the following: 1) practice abstinence from heterosexual activity, or 2) use acceptable
contraception during heterosexual activity

- For inclusion in Study Extension 1 (optional): completed the Week 48 visit; considered
to have derived benefit from study participation up to Week 48; considered to be a
clinically appropriate candidate for an additional 2 years treatment with study drug

- For inclusion in Study Extension 2 (optional): completed the Week 144 visit;
considered to have derived benefit from study participation up to Week 144; considered
to be a clinically appropriate candidate for an additional 2 years treatment with
study drug

Exclusion Criteria:

- Uses recreational or illicit drugs or has a recent history of drug or alcohol abuse or
dependence

- Received treatment for a viral infection other than HIV-1, such as hepatitis B, with
an agent that is active against HIV-1 such as adefovir, emtricitabine, lamivudine, or
tenofovir

- Has documented or known resistance to study drugs including doravirine, lamivudine,
and/or tenofovir

- Participated in a study with an investigational compound or device within 30 days or
anticipates doing so during the course of this study

- Used systemic immunosuppressive therapy or immune modulators within 30 days or
anticipates needing them during the course of this study (short courses of
corticosteroids will be allowed)

- Current, active diagnosis of acute hepatitis due to any cause (participants with
chronic hepatitis B and C may enter the study as long as they fulfill all entry
criteria, have stable liver function tests, and have no significant impairment of
hepatic function)

- Has evidence of decompensated liver disease or has liver cirrhosis and a Child-Pugh
Class C score or Pugh-Turcotte score >9

- Pregnant, breastfeeding, or expecting to conceive at any time during the study

- Female and is expecting to donate eggs or male and is expecting to donate sperm during
the study